| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Isoastragaloside II targets osteogenic differentiation pathways, reported to have osteogenic properties that promote bone formation, and is a derivative of astragaloside I, with potential applications in bone health and osteoporosis research.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Isoastragaloside II exhibits osteogenic properties, promoting the differentiation of osteoblast precursor cells and enhancing bone formation markers, though detailed mechanistic and potency data are less extensively reported compared to other astragalosides.
|
| ln Vivo |
In vivo studies on Isoastragaloside II are limited; however, related astragalosides have shown bone-protective effects in animal models of osteoporosis, suggesting potential in vivo efficacy for Isoastragaloside II in bone health applications.
|
| Enzyme Assay |
The in vitro osteogenic differentiation assay involves treating mesenchymal stem cells or osteoblast precursor cells (e.g., MC3T3-E1) with Isoastragaloside II, assessing alkaline phosphatase activity by colorimetric assay, mineralization by alizarin red S staining, and osteogenic gene expression (Runx2, Osterix, osteocalcin) by qPCR.
|
| Cell Assay |
In vitro cell culture studies utilize osteoblast cell lines or primary bone marrow stromal cells treated with Isoastragaloside II at various concentrations, measuring cell proliferation by MTT, differentiation by ALP activity and mineralization staining, and signaling pathway activation (e.g., BMP/Smad, Wnt/β-catenin) by Western blotting.
|
| Animal Protocol |
In vivo animal experiments for evaluating osteogenic compounds typically involve ovariectomized rat models of osteoporosis, with administration of Isoastragaloside II via oral gavage or intraperitoneal injection, followed by assessment of bone mineral density by DXA, micro-CT analysis of bone microarchitecture, and histological examination of bone sections.
|
| ADME/Pharmacokinetics |
Isoastragaloside II is a triterpenoid saponin with molecular weight 827.01 g/mol and molecular formula C43H70O15; it has very low aqueous solubility (0.035 g/L at 25°C), is soluble in organic solvents such as DMSO and methanol, and is typically stored as a solid powder at room temperature with purity ≥98% (HPLC).
|
| Toxicity/Toxicokinetics |
Toxicological data for Isoastragaloside II are limited; as a saponin compound from Astragalus membranaceus, it is generally considered to have low toxicity, though comprehensive safety profiles in animals have not been extensively reported for this specific compound.
|
| Additional Infomation |
Isoflavone II is a glycoside and cucurbitacin. It has been reported that isoflavone II exists in Astragalus membranaceus, Astragalus mongholicus, and Astragalus siberianus, and relevant data are available for reference.
Isoastragaloside II is a research compound used as a reference standard for quality control of Astragalus membranaceus and related herbal products; it has potential applications in osteogenic research and bone health studies, though it has not been approved for clinical use. |
| Molecular Formula |
C43H70O15
|
|---|---|
| Molecular Weight |
827.0069
|
| Exact Mass |
826.471
|
| CAS # |
86764-11-6
|
| PubChem CID |
60148655
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
905.4±65.0 °C at 760 mmHg
|
| Flash Point |
264.0±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.608
|
| LogP |
1.34
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
58
|
| Complexity |
1580
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
CC(=O)O[C@H]1[C@@H](CO[C@H]([C@@H]1O)O[C@H]2CC[C@]34C[C@]35CC[C@@]6([C@H]([C@H](C[C@]6([C@@H]5C[C@@H]([C@H]4C2(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)O)[C@]8(CC[C@H](O8)C(C)(C)O)C)C)O
|
| InChi Key |
SMZYCXAYGPGYRS-NGTUZWGPSA-N
|
| InChi Code |
InChI=1S/C43H70O15/c1-20(45)54-32-22(47)18-53-35(31(32)51)57-26-10-12-43-19-42(43)14-13-39(6)33(41(8)11-9-27(58-41)38(4,5)52)21(46)16-40(39,7)25(42)15-23(34(43)37(26,2)3)55-36-30(50)29(49)28(48)24(17-44)56-36/h21-36,44,46-52H,9-19H2,1-8H3/t21-,22+,23-,24+,25-,26-,27-,28+,29-,30+,31+,32-,33-,34-,35-,36+,39+,40-,41+,42-,43+/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5R)-3,5-dihydroxy-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-9-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]oxan-4-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~60.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.02 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2092 mL | 6.0459 mL | 12.0918 mL | |
| 5 mM | 0.2418 mL | 1.2092 mL | 2.4184 mL | |
| 10 mM | 0.1209 mL | 0.6046 mL | 1.2092 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
